Pooled human immunoglobulin
Normal immunoglobulin (IVIG / SCIG)
Brand names: Privigen, Octagam, Hizentra, Cuvitru
Adult dose
Dose: Replacement (PID): 0.4–0.8 g/kg IV every 3–4 weeks. ITP: 0.8–1g/kg IV repeat day 3 if needed. GBS/MG/CIDP: 0.4 g/kg/day IV for 5 days
Route: IV/SC
Frequency: varies
Clinical pearls
- Replacement therapy in primary/secondary immunodeficiency; immunomodulation in autoimmune disease
- Strict UK national IVIG demand management — specialist authorisation
Contraindications
- IgA deficiency with anti-IgA antibodies
- Hypersensitivity
Side effects
- Anaphylaxis
- Aseptic meningitis
- Thromboembolism
- Haemolysis
- Acute kidney injury (older sucrose-stabilised products)
- TRALI
Interactions
- Live vaccines (delay 3 months)
Monitoring
- U&E
- Hb
- BP during infusion
- Hydration
Reference: BNF; UK National Demand Management Programme; https://bnf.nice.org.uk/drugs/normal-immunoglobulin/. Verify against your local formulary and the latest BNF before prescribing.
Related
Curated clinical cross-links plus same-class fallbacks.
Calculators
- ACC/AHA Pooled Cohort Equations — ASCVD Risk · Cardiovascular Risk
- PCP-HF Risk Score (Pooled Cohort Equations to Prevent Heart Failure) · Heart Failure Prevention
- ACC/AHA Pooled Cohort Equations (ASCVD Risk) · Cardiovascular Risk
- Erasmus GBS Outcome Score (EGOS) · Guillain-Barre Syndrome
- Autoimmune Encephalitis Probability Score · Encephalitis
- Kawasaki Disease Diagnostic Criteria · Paediatric Infectious Disease
Pathways
- Major Haemorrhage / Massive Transfusion · BCSH; RCOA; RCEM; RCS — BCSH Guidelines
- Anaemia Investigation · BSH / NICE
- Splenomegaly Workup · BSH; BMJ Best Practice
- Deep Vein Thrombosis Diagnosis and Treatment · NICE CG144 / NICE NG158
- Sickle Cell Crisis · BSH 2021 / BCSH
- Neutropenic Sepsis · NICE CG151 2012 / ESMO